
|Videos|May 1, 2019
Assessing the Role of 21-Gene Assays in Breast Cancer
Author(s)John H. Ward, MD
John H. Ward, MD, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.
Advertisement
John H. Ward, MD, Margaret A. Amundsen Endowed Professor of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.
Patients who have a low 21-gene recurrence score can be spared chemotherapy. It is predicted that 46% of women with breast cancer can forego chemotherapy, according to Ward.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































